Singapore Biotech Helps 13-Year-Old Avoid Repeat Surgery

A 13-year-old girl who received a liver transplant as a baby faced a terrifying question in early 2026: had her new organ begun to fail? Her doctors turned to Singapore biotech company HistoIndex for answers, and the technology revealed only minimal scarring, sparing the family from the worry of another major procedure.

That reassuring diagnosis came from 16 years of research that transformed complex science into something doctors can actually use. HistoIndex's Genesis200 imaging system examines liver tissue without traditional staining, helping physicians measure disease progression and treatment effectiveness with AI-powered precision.

The company's journey from lab to clinic shows how Singapore is bridging the gap between medical research and real patient care. Enterprise Singapore supported HistoIndex as it validated its technology against established medical standards, helping the firm prove its tools worked consistently across different clinical settings.

Today, HistoIndex partners with major institutions including Peking University and Mt Sinai Health System in New York. Its customer base has grown to include 21 large pharmaceutical companies, 20 biotech firms, and 60 universities and hospitals worldwide.

Another Singapore company, Kyan Technologies, is pushing precision medicine even further. Its Optim.AI platform tests cancer drugs on a patient's actual tumor cells outside the body, helping doctors identify which treatments might work best before prescribing them.

Results typically arrive within seven to 10 days, giving oncologists crucial information to guide treatment decisions. Since launching commercial services in 2023 after receiving government licensing and international accreditation, Kyan's laboratory has supported tests from more than 10 countries and nearly 200 clinicians worldwide.

The technology started as research in the US before moving to the National University of Singapore in 2013. Clinical studies began in 2016, but commercialization took another six years as the team worked to prove the approach delivered reliable results.

The Ripple Effect

Singapore's precision medicine sector is growing as part of the country's $32 billion biomedical sciences industry. The global precision medicine market is expected to jump from $100 billion today to $266 billion by 2034, driven by advances in genomics, artificial intelligence, and digital health tools.

Hugo Saavedra, Kyan's co-founder and CEO, says the pathway from research to commercial use has strengthened significantly over the past decade. Enterprise Singapore has helped his company navigate new healthcare markets and connect with potential clinical partners, including teams at Mayo Clinic.

"Without support from Enterprise Singapore, Kyan would be pursuing the same mission more slowly, with greater execution risk and under more financing pressure," Saavedra explains. The agency has worked like an extended team, providing strategy insights and market knowledge.

HistoIndex co-founder Dr. Gideon Ho credits similar support for helping his company expand internationally. The backing enabled his team to strengthen their AI analytics and validate their approach using clinically relevant datasets, building the foundation for partnerships with pharmaceutical companies and research institutions.

Both companies now face the same challenge: proving their technologies deliver consistent results across different healthcare systems and patient populations around the world, turning today's innovations into tomorrow's standard of care.